Jing Chen

Dr. Jing Chen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2020 in Gut
Verified
Journal Article
Open access
PDF file
JCJing Chen
Jing Chen
YJYang Jiang
Yang Jiang
TCTse-Shao Chang
Tse-Shao Chang
BJBishnu Joshi
Bishnu Joshi
JZJuan Zhou
Juan Zhou
TWThomas Wang
Thomas Wang
Improved methods for early cancer detection arising from Barrett’s oesophagus (BE) are still needed. Imaging molecular expression patterns in BE patients can target neoplasia. We demonstrate a multiplexed fluorescence imaging approach to detect premalignant lesions with two fluorescently labeled heptapeptides specific for EGFR and ErbB2. Twenty-two BE patients underwent endoscopic imaging with a multimodal scanning fiber endoscope (mmSFE). In this pilot study, 92% of neoplastic lesions could be imaged by comparison with pathology, with only 11% false positives. This first-in-human study demonstrates feasibility to concurrently detect multiple targets in vivo and potential for early detection of cancers that are molecularly heterogeneous.

28 December 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
JCJing Chen
Jing Chen
PJPeng Ji
Peng Ji
GGGiri Gnawali
Giri Gnawali
MCMengyang Chang
Mengyang Chang
FGFeng Gao
Feng Gao
WWWei Wang
Wei Wang
The current targeting drug delivery mainly relies on cancer cell surface receptors. However, in many cases, binding affinities between protein receptors and homing ligands is relatively low and the expression level between cancer and normal cells is not significant. Distinct from conventional targeting strategies, we have developed a general cancer targeting platform by building artificial receptor on cancer cell surface via a chemical remodeling of cell surface glycans. A new tetrazine (Tz) functionalized chemical receptor has been designed and efficiently installed on cancer cell surface as “overexpressed” biomarker through a metabolic glycan engineering. Different from the reported bioconjugation for drug targeting, the tetrazine labeled cancer cells not only locally activate TCO-caged prodrugs but also release active drugs via the unique bioorthogonal Tz-TCO click-release reaction. The studies have demonstrated that the new drug targeting strategy enables local activation of prodrug, which ultimately leads to effective and safe cancer therapy.

25 October 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JCJing Chen
Jing Chen
VNVan Phuc Nguyen
Van Phuc Nguyen
SJSangeeta Jaiswal
Sangeeta Jaiswal
XKXiaoyu Kang
Xiaoyu Kang
MLMiki Lee
Miki Lee
TWThomas Wang
Thomas Wang
The large size of nanoparticles prevents rapid extravasation from blood vessels and diffusion into tumors. Multimodal imaging uses the physical properties of one modality to validate the results of another. We aim to demonstrate the use of a targeted thin layer-protected ultra-small gold nanoparticles (Au-NPs) to detect cancer in vivo using multimodal imaging with photoacoustic and computed tomography (CT). The thin layer was produced using a mixed thiol-containing short ligands, including MUA, CVVVT-ol, and HS-(CH2)11-PEG4-OH. The gold nanoparticle was labeled with a heterobivalent (HB) peptide ligand that targets overexpression of epidermal growth factor receptors (EGFR) and ErbB2, hereafter HB-Au-NPs. A human xenograft model of esophageal cancer was used for imaging. HB-Au-NPs show spherical morphology, a core diameter of 4.47 ± 0.8 nm on transmission electron microscopy, and a hydrodynamic diameter of 6.41 ± 0.73 nm on dynamic light scattering. Uptake of HB-Au-NPs was observed only in cancer cells that overexpressed EGFR and ErbB2 using photoacoustic microscopy. Photoacoustic images of tumors in vivo showed peak HB-Au-NPs uptake at 8 h post-injection with systemic clearance by ~48 h. Whole-body images using CT validated specific tumor uptake of HB-Au-NPs in vivo. HB-Au-NPs showed good stability and biocompatibility with fast clearance and contrast-enhancing capability for both photoacoustic and CT imaging. A targeted thin layer-protected gold nanoprobe represents a new platform for molecular imaging and shows promise for early detection and staging of cancer.

20 June 2022 in Endoscopy
Verified
Journal Article
Open access
PDF file
JCJing Chen
Jing Chen
YJYang Jiang
Yang Jiang
TCTse-Shao Chang
Tse-Shao Chang
JRJoel H. Rubenstein
Joel H. Rubenstein
RKRichard S. Kwon
Richard S. Kwon
TWThomas Wang
Thomas Wang
Background Esophageal adenocarcinoma (EAC) is a molecularly heterogeneous disease with poor prognosis that is rising rapidly in incidence. We aimed to demonstrate specific binding by a peptide heterodimer to Barrett’s neoplasia in human subjects. Methods Peptide monomers specific for EGFR and ErbB2 were arranged in a heterodimer configuration and labeled with IRDye800. This near-infrared (NIR) contrast agent was topically administered to patients with Barrett’s esophagus (BE) undergoing either endoscopic therapy or surveillance. Fluorescence images were collected using a flexible fiber accessory passed through the instrument channel of an upper gastrointestinal endoscope. Fluorescence images were collected from 31 BE patients. A deep learning model was used to segment the target (T) and background (B) regions. Results The mean target-to-background (T/B) ratio was significantly greater for high grade dysplasia (HGD) and EAC versus BE, low grade dysplasia (LGD), and squamous epithelium. At a T/B ratio of 1.5, sensitivity and specificity of 94.1 % and 92.6 %, respectively, were achieved for the detection of Barrett’s neoplasia with an area under the curve of 0.95. No adverse events attributed to the heterodimer were found. EGFR and ErbB2 expression were validated in the resected specimens. Conclusions This “first-in-human” clinical study demonstrates the feasibility of detection of early Barrett’s neoplasia using a NIR-labeled peptide heterodimer.

8 October 2018 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
JCJing Chen
Jing Chen
ZGZhenghong Gao
Zhenghong Gao
GLGaoming Li
Gaoming Li
TWThomas Wang
Thomas Wang
A heterodimeric peptide labeled with IRDye800 is used to perform dual-modal imaging of human esophageal xenograft tumors in vivo. Fluorescence and photoacoustic images provide complementary visualization of tumor dimensions in planar and sagittal views, respectively, demonstrating promise for targeted cancer diagnosis and staging.

5 June 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JCJing Chen
Jing Chen
JZJuan Zhou
Juan Zhou
ZGZhenghong Gao
Zhenghong Gao
XLXue Li
Xue Li
FWFa Wang
Fa Wang
TWThomas Wang
Thomas Wang